Valiant Organics Q1FY27 profit up 188% to ₹29.26 cr YoY

What Valiant Organics reported for Q1FY27

Valiant Organics has reported a sharp year-on-year rise in profitability for the quarter ended June 30, 2026 (Q1FY27). In its unaudited financial results, the company reported consolidated revenue from operations of ₹231.54 crore and consolidated net profit of ₹29.26 crore. The filing also disclosed basic EPS of ₹10.44 on a consolidated basis. On a standalone basis, revenue from operations was ₹231.54 crore, standalone net profit was ₹21.82 crore, and standalone basic EPS was ₹7.79.

Alongside the financial numbers, the company updated its segment reporting by identifying ‘Pharma Business’ as a distinct reportable segment, in addition to its existing Speciality Chemical Division. The board also approved the re-appointment of Shri Sathiababu K. Kallada as Managing Director for a three-year term effective May 2027.

Profit and margin expansion: the key theme

The results commentary points to margin expansion as a key driver of the profit jump. One section of the provided material states that standalone net profit rose 186.84% YoY to ₹21.8 crore for the quarter ended June 30, 2026, supported by an EBITDA margin expansion of 583 basis points to 17.98%. Separately, a table in the material shows EBITDA margin at 17.97% for Q1FY27 versus 12.13% in Q1FY26, an increase of 584 bps.

The same table lists EBITDA of ₹416 crore for Q1FY27 versus ₹248 crore for Q1FY26, alongside revenue of ₹2,315 crore versus ₹2,044 crore. These values conflict with the other figures in the provided content that repeatedly cite consolidated revenue around ₹231 crore and net profit around ₹29 crore for the June 2026 quarter. The company’s earnings presentation was noted as being filed with stock exchanges on August 21, 2026, and described as highlighting “significant margin expansion.”

Multiple result snapshots in circulation

The material includes more than one snapshot of Valiant Organics’ Q1FY27 performance, with different profit and revenue values presented in different places. One line states the company reported a consolidated net profit of ₹293 crore for the quarter ended June 30, 2026, up 257% from ₹82 crore. In other places, the reported Q1FY27 profit is ₹29.26 crore (up 188% from ₹8.20 crore) or ₹22 crore (up 190.72% from ₹7 crore), with revenue reported at ₹231 crore (about 13% growth).

Because these numbers are not consistent within the provided text, they are best read as separate reported summaries. The consistent operational datapoint repeated across multiple sections is revenue in the ₹231–₹231.54 crore range for the June 2026 quarter, along with profit growth of roughly ~188% to ~191% YoY in the ₹22–₹29 crore range.

Key operating details mentioned: gross profit and Pharma turnaround

One part of the content states revenue climbed 13% to ₹231 crore in the June 2026 quarter, with gross profit expanding to ₹31 crore. Another portion attributes consolidated profitability to a turnaround in the Pharma division and strong performance from associate companies. The provided text gives two different Pharma segment profit figures: it mentions a segment profit of ₹16.85 crore in one place and a Pharma segment result of ₹8.99 crore in another, both described in the context of the segment moving into profit.

The company also communicated a reporting change by carving out Pharma Business as a separate reportable segment, which typically helps investors track segment economics more clearly when businesses have different margin profiles.

Dates, filings, and stock levels cited

The material mentions that Q1FY27 results were declared on August 12, 2026. It also says the earnings presentation was filed with stock exchanges on August 21, 2026. On the market side, the content states Valiant Organics shares were trading at ₹341.55 on August 12, 2026, the day results were announced.

A separate line in the provided content answers a price query by stating the “current share price” of Valiant Organics is ₹317.8. No intraday move, percentage change, or volume data is included in the text.

No dividend declared with Q1FY27 results

The content explicitly states that no dividend has been announced along with Valiant Organics’ Q1FY27 results for the quarter ended June 2026. Separately, a historical dividend reference appears: in the quarter ending December 2022, the company declared a dividend of ₹1.00 per share on January 31, 2023, with a stated dividend yield of 1.45%. The June 2026 quarter, however, carried no dividend announcement per the provided text.

Summary table of reported Q1 metrics (as stated)

The figures below are reproduced as they appear in the provided material, including where different sections report different values for the same quarter.

Why the segment reporting change matters

The decision to identify Pharma Business as a separate reportable segment is a noteworthy disclosure alongside the quarterly numbers. When a business turns profitable after losses, segment separation can make that shift more visible in future quarters. The text links consolidated profitability to the Pharma turnaround and to performance from associate companies, indicating that the earnings improvement is not being attributed only to the core speciality chemicals operations.

The management update is also specific: the board approved the re-appointment of Shri Sathiababu K. Kallada as Managing Director effective May 2027 for three years. Another line mentions appointment of a “new Managing Director,” but no name is provided in the text.

Market impact and what investors can track next

From the facts provided, the immediate investor-facing takeaways are the sharp YoY increase in profit, the margin expansion to around 18% EBITDA margin, and the visibility added through new segment reporting. With the stock cited at ₹341.55 on the result date and a later “current” price reference of ₹317.8, the text indicates investors were also watching price levels around the announcement.

The next formal reference point mentioned in the material is the earnings presentation filed on August 21, 2026, which was described as highlighting margin expansion. Investors typically use such presentations to cross-check segment performance, margin drivers, and any commentary on business conditions, but the provided text does not include additional guidance or outlook.

Conclusion

Valiant Organics’ Q1FY27 disclosures point to materially higher profitability versus last year, margin expansion to about 18%, and a reporting shift that separates the Pharma Business as its own segment. The company also confirmed leadership continuity through the re-appointment of Shri Sathiababu K. Kallada as Managing Director effective May 2027. With no dividend announced for the June 2026 quarter, attention is likely to remain on subsequent filings for clearer segment-level trends and consistency across reported metrics.